Kineticos Disruptor Fund II GP is the general partner of Kineticos Disruptor Fund II, part of the Kineticos Life Sciences platform based in Raleigh, North Carolina. Kineticos operates multiple specialized funds targeting the life sciences ecosystem, with the Disruptor Funds specifically focused on advancing groundbreaking technologies to treat cancer, neurodegenerative diseases, and rare diseases. The firm is led by seasoned life sciences operators, executives, and investors with deep scientific, business, and operational expertise. Kineticos combines financial acumen with hands-on operational support, leveraging a network of proven industry experts to guide portfolio companies at every stage of the business lifecycle. The platform's recent investments include Inceptor Bio (cell therapy for renal cell carcinoma) and the launch of Kinvard Bio (next-generation antibiotics).
Profile auto-generated from public sources — details unverified.